Regulatory Roundup: FDA holds meeting to discuss dosing information for OTC drugs containing acetaminophen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA holds meeting to discuss dosing information for OTC drugs containing acetaminophen

ePT--the Electronic Newsletter of Pharmaceutical Technology

Last week, FDA held a joint meeting of its Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee to discuss whether new dosing information for oral over-the-counter (OTC) drug products containing acetaminophen should be added to the label for children under age 2. The full meeting agenda is here. Johnson & Johnson’s McNeil Consumer Healthcare, which recalled several children’s OTC products during the past year, provided briefing materials for the meeting, which can be accessed online. At press time, minutes of the meeting had not been posted. Reportedly, the committee recommended adding dosing guidelines to products containing acetaminophen for children under age 2, including Children’s Tylenol. The panel also recommended that dosage labels be revised according to weight, not age, for these products. FDA does not have to accept the panel’s recommendations, but typically does.

Excipact, Rx-360, and IPEA are collaborating on the use of a self-regulated and voluntary audit scheme based on the widely accepted IPEC-PQG GMP and GDP Guides according to a May 24 press release. The goal is to help improve patient safety and global supply chain security. IPEA is the arm of the International Pharmaceutical Excipients Council (IPEC) that focuses on auditing. Excipact is an international group of excipients manufactures, suppliers, and distributors, including the IPEC regional organizations. The audit scheme is based upon the new Excipact standard, launching this year, and the pending equivalent ANSI NSF363 standard, says the release. The Excipact standard includes additional requirements for GMP and GDP certification and is based on the ISO 9001 Quality Management System Standard.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here